Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04041050
Title A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

polycythemia vera

chronic myelomonocytic leukemia

myelofibrosis

essential thrombocythemia

Therapies

Navitoclax

Navitoclax + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.